Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 9/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 8/20 | 0.35 |
| ▸ | MAOA | P21397 | 7/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283381 | 1.00 | NFKB1 (0.39) | NFKB1NFKB2RELAMAOBADORA3 | |
| SCHEMBL3355775 | 0.79 | AR (0.42) | MAOBADORA3ARMAOACYP3A4 | |
| SCHEMBL5914697 | 0.78 | MAOB (0.38) | MAOBKDM1AMAOA | |
| SCHEMBL28942665 | 0.78 | MAOB (0.40) | NFKB1NFKB2RELAMAOBADORA3 | |
| SCHEMBL30728429 | 0.77 | GABRA1 (0.52) | KDM4EHSP90AB1MAPTRAB9A | |
| SCHEMBL30146748 | 0.77 | MAOA (0.39) | MAOBMAOA | |
| SCHEMBL7557445 | 0.77 | MAOA (0.39) | MAOBMAOA | |
| SCHEMBL6907553 | 0.76 | KDM1A (0.36) | NFKB1NFKB2RELAMAOBKDM4E | |
| SCHEMBL29008599 | 0.76 | MAOB (0.38) | NFKB1NFKB2RELAMAOBADORA3 | |
| SCHEMBL3129322 | 0.72 | SIGMAR1 (0.33) | CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560342-B2 | Bacillus isolates and uses thereof | MONSANTO TECHNOLOGY, LLC (US) | 2023-01-24 | — | — | US | claimed |
| EP-3894018-B1 | TOPICAL, ISOTONIC COMPOSITIONS FOR GENITAL USE | GLYCIOME LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4719594-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | Glyciome, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260076922-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | GLYCIOME LLC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12576096-B2 | Topical, isotonic compositions for genital use | GLYCIOME, LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250235164-A1 | METHOD OF PROVIDING SUSTAINED ENERGY | PEPSICO, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| US-20250212885-A1 | FORMULATIONS WITH COLLOIDAL SILVER | AMERICAN SILVER LLC (US) | 2025-07-03 | — | — | US | disclosed |
| US-12250949-B2 | Formulations with colloidal silver | AMERICAN SILVER, LLC (US) | 2025-03-18 | — | — | US | disclosed |
| WO-2024249580-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | GLYCIOME, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| US-12083304-B2 | Kits for topical, isotonic compositions | GLYCIOME, LLC (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118435303-A | Electrolytic capacitor and liquid component for electrolytic capacitor | 松下知识产权经营株式会社 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024101192-A1 | COMPOSITE RESIN COMPOSITION, METHOD FOR PRODUCING SAME, INSULATING RESIN COMPLEX AND POWER APPARATUS USING SAME | 株式会社日立製作所 | 2024-05-16 | — | — | WO | disclosed |
| CN-108473940-B | Stable inoculant compositions and methods of producing the same | 诺维信生物农业公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230255210-A1 | FORMULATIONS WITH COLLOIDAL SILVER | AMERICAN SILVER LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230039637-A1 | MICROBIOME OPTIMIZATION | GLYCIOME, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11564395-B2 | Formulations with colloidal silver | AMERICAN SILVER, LLC (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4081664-A1 | MICROBIOME OPTIMIZATION | Glyciome, LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114173797-A | Product infused with cannabis with enhanced cannabinoid profile user experience | 埃克索运营公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576096-B2 | Topical, isotonic compositions for genital use | MAN2B2, AP1S1, MAN2A1 | NFKB1 1233/4885NFKB2 1106/4885RELA 317/4885 |
| US-11560342-B2 | Bacillus isolates and uses thereof | BLVRB, BROX, GLB1 | NFKB1 2378/4885NFKB2 2523/4885RELA 1838/4885 |
| US-20260076922-A1 | DECREASING ACINETOBACTER POPULATIONS IN THE MICROBIOME | MAN2B2, ALG3, FUCA1 | NFKB1 1759/4885NFKB2 804/4885RELA 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.